We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+6.98%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$368M
AUM Growth
+$18.7M
Cap. Flow
+$14.9M
Cap. Flow %
4.04%
Top 10 Hldgs %
6.4%
Holding
553
New
113
Increased
199
Reduced
149
Closed
92

Top Buys

Rank Stock Value
1
EXPD icon
Expeditors International
EXPD
+$2.17M
2
INCY icon
Incyte
INCY
+$2.09M
3
WAT icon
Waters Corp
WAT
+$2.03M
4
AMAT icon
Applied Materials
AMAT
+$2.01M
5
LVS icon
Las Vegas Sands
LVS
+$2.01M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$2.5M
2
EA
Electronic Arts
EA
+$2.43M
3
FOXA icon
Fox Class A
FOXA
+$2.05M
4
MS icon
Morgan Stanley
MS
+$2.04M
5
ATO icon
Atmos Energy
ATO
+$2.02M

Sector Composition

Rank Sector Weight
1 Healthcare 26.73%
2 Financials 22.73%
3 Technology 18.16%
4 Industrials 8.89%
5 Consumer Discretionary 7.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
351
MoonLake Immunotherapeutics
MLTX
$1.46B
$237K 0.06%
17,987
+15,402
+596% +$182K
SLNO
352
DELISTED
Soleno Therapeutics
SLNO
$237K 0.06%
5,116
+3,697
+261% +$203K
MNPR icon
353
Monopar Therapeutics
MNPR
$781M
$233K 0.06%
+3,565
New +$291K
ORIC icon
354
Oric Pharmaceuticals
ORIC
$1.43B
$232K 0.06%
28,361
+16,594
+141% +$191K
SVRA icon
355
Savara
SVRA
$1.16B
$232K 0.06%
38,443
-11,906
-24% -$58.3K
FULC icon
356
Fulcrum Therapeutics
FULC
$288M
$231K 0.06%
+20,463
New +$208K
CGEM icon
357
Cullinan Oncology
CGEM
$1.17B
$231K 0.06%
22,318
+9,604
+76% +$86.6K
KYMR icon
358
Kymera Therapeutics
KYMR
$9.02B
$231K 0.06%
2,966
+560
+23% +$37.8K
IRON icon
359
Disc Medicine
IRON
$2.99B
$230K 0.06%
2,897
+739
+34% +$62.4K
GOSS icon
360
Gossamer Bio
GOSS
$87.5M
$229K 0.06%
+73,896
New +$211K
ALMS
361
Alumis Inc
ALMS
$3.5B
$226K 0.06%
+23,153
New +$162K
PRME icon
362
Prime Medicine
PRME
$575M
$225K 0.06%
+64,886
New +$289K
COGT icon
363
Cogent Biosciences
COGT
$7.08B
$224K 0.06%
6,317
-9,443
-60% -$265K
AVBP icon
364
ArriVent BioPharma
AVBP
$1.44B
$219K 0.06%
10,894
+6,078
+126% +$127K
VSTM icon
365
Verastem
VSTM
$604M
$214K 0.06%
+27,682
New +$247K
SANA icon
366
Sana Biotechnology
SANA
$1B
$211K 0.06%
51,756
+6,958
+16% +$31.2K
NKTR icon
367
Nektar Therapeutics
NKTR
$2.53B
$206K 0.06%
+4,863
New +$272K
OLMA icon
368
Olema Pharmaceuticals
OLMA
$1.05B
$201K 0.05%
8,049
-19,977
-71% -$355K
FDMT icon
369
4D Molecular Therapeutics
FDMT
$582M
$184K 0.05%
+24,541
New +$249K
ALT icon
370
Altimmune
ALT
$591M
$182K 0.05%
50,482
+34,568
+217% +$151K
HPK icon
371
HighPeak Energy
HPK
$1.01B
$174K 0.05%
+36,621
New +$220K
CNQ icon
372
Canadian Natural Resources
CNQ
$97.7B
$170K 0.05%
5,029
-348
-6% -$11.3K
EGY icon
373
Vaalco Energy
EGY
$620M
$170K 0.05%
+46,724
New +$173K
KNTK icon
374
Kinetik
KNTK
$8.29B
$170K 0.05%
+4,705
New +$170K
AXIA
375
DELISTED
AXIA Energia
AXIA
$168K 0.05%
+18,373
New +$159K
13 14
15
16 17

Similar funds

WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
RGC
Roberts, Glore & Co Deerfield, Illinois $364M AUM 19.54% 1-Year Est. Return

Virtus Investment Advisers's Q4 2025 Portfolio in Review

As of Q4 2025, Virtus Investment Advisers held 553 positions worth $368M, up 5.3% from $349M the previous quarter. Its ten largest holdings account for 6.4% of the portfolio.

Virtus Investment Advisers deployed $14.9M of net new capital in Q4 2025, opening 113 new positions and adding to 199 existing holdings. Its largest new stake was Expeditors International: 15,974 shares worth $2.38M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 17% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was VICI Properties, an estimated $1.66M trimmed.

  • Virtus Investment Advisers's largest Q4 2025 buy was Expeditors International: 15,974 shares worth $2.38M.
  • Virtus Investment Advisers added most to Incyte in Q4 2025, an estimated $2.09M increase.
  • Virtus Investment Advisers's biggest Q4 2025 reduction was VICI Properties, cutting an estimated $1.66M.
  • Virtus Investment Advisers fully exited Tesla in Q4 2025, selling an estimated $2.5M.
  • Virtus Investment Advisers's ten largest holdings make up 6.4% of its $368M portfolio in Q4 2025.
  • Virtus Investment Advisers opened 113 new positions and closed 92 in Q4 2025.
  • Virtus Investment Advisers's portfolio value rose 5.3% quarter-over-quarter to $368M.

Based on Virtus Investment Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.